ReviewVascular health and risk management2007
Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.
Review in Vascular health and risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The effect of cumulative exposure to unhealthy behavioral lifestyles on incident primary dyslipidemia: a prospective study from the Chinese government employee cohort.Lipids in health and disease · 2025Article
- A Case of Diabetes With a Rare Variant of Familial Combined Hyperlipidemia With an Atypical Phenotype.Cureus · 2025Article
- Article
- Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Hyperlipidemia and Cardiovascular Risk in Children and Adolescents.Biomedicines · 2023Review
- Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update.Biochemical genetics · 2022Review
- Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.Current atherosclerosis reports · 2021Review
- Carotid Atherosclerosis, Ultrasound and Lipoproteins.Biomedicines · 2021Review
- Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.Journal of the Endocrine Society · 2020Article
- Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied.Frontiers in cardiovascular medicine · 2018Review
- Moyamoya Disease with Coexistent Hypertriglyceridemia in Pediatric Patient.Case reports in endocrinology · 2016Article
- [Familial combined hyperlipidemia: consensus document].Atencion primaria · 2014Article
- Management of hypercholesterolemia in children.Paediatric drugs · 2014Review
- Immunosuppression in renal transplantation and dyslipidemia, which factors should be considered?Nephro-urology monthly · 2013Article
- Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate.Archives of medical science : AMS · 2013Article
- Adipocyte triglyceride turnover is independently associated with atherogenic dyslipidemia.Journal of the American Heart Association · 2012Article
- Postprandial metabolic heterogeneity in men with primary dyslipidaemia.Archives of medical science : AMS · 2010Article
- Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.Lancet (London, England) · 2010Article
- New technologies for delineating and characterizing the lipid exome: prospects for understanding familial combined hyperlipidemia.Journal of lipid research · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial combined hyperlidemia (FCH) is a common metabolic disorder characterized by: (a) increase in cholesterolemia and/or triglyceridemia in at least two members of the same family, (b) intra-individual and intrafamilial variability of the lipid phenotype, and (c) increased risk of premature coronary heart disease (CHD). FCH is very frequent and is one of the most common genetic hyperlipidemias in the general population (prevalence estimated: 0.5%-2.0%), being the most frequent in patients affected by CHD (10%) and among acute myocardial infarction survivors aged less than 60 (11.3%). This percentage increases to 40% when all the myocardial infarction survivors are considered without age limits. However, because of the peculiar variability of laboratory parameters, and because of the frequent overlapping with the features of metabolic syndrome, this serious disease is often not recognized and treated. The aim of this review is to define the main characteristics of the disease in order to simplify its detection and early treatment by all physicians by mean of practical guidelines.
Indexed as
Identifiers
18200807PMC2350131What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.